Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | ($2.2) | ($1.2) | ($0.9) | ($1.0) | ($2.0) | ($2.1) | ($0.3) | ($1.5) | ($0.3) | ($0.6) | ($0.3) | $0.0 | $0.6 | ($1.5) | $0.5 | $2.1 | ($1.4) | $4.3 | $1.5 | $2.7 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Incyte Corporation's last 12-month EPS is $0.2, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Incyte Corporation's EPS growth was (91.0%). The average annual EPS growth rates for Incyte Corporation have been (57.3%) over the past three years, (38.2%) over the past five years.
Over the last year, Incyte Corporation's EPS growth was (91.0%), which is lower than industry growth of (0.2%). It indicates that Incyte Corporation's EPS growth is Bad.